Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Capivasertib/Fulvestrant Approval Expands Options in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

December 22nd 2023

Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

December 22nd 2023

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer

December 21st 2023

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

December 21st 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

Evolving Treatment Paradigms for Early-Stage Breast Cancers

December 20th 2023

Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.

Addition of Tucatinib to Breast Cancer Maintenance Therapy Aims to Fill Unmet Need for Patients With Brain Metastases

December 20th 2023

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.

Dr Brufsky on the FDA Approval of Capivasertib Plus Fulvestrant in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

December 19th 2023

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the FDA approval of capivasertib in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

December 19th 2023

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

An Overview of HR+, HER2- Metastatic Breast Cancer

December 18th 2023

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.

Dr Bardia on the Efficacy and Safety of Dato-DXd in HR+/HER2– Breast Cancer

December 15th 2023

Aditya Bardia, MD, MPH, discusses key efficacy results from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

Dr Tolaney on the Real-World Efficacy of T-DXd in HER2+ or HER2-Low Breast Cancer

December 15th 2023

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

December 9th 2023

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC

December 8th 2023

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC

December 8th 2023

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer.

Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS

December 8th 2023

Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.

EFS Benefit With Neoadjuvant Pembrolizumab/Chemo Combo, Adjuvant Pembrolizumab Upheld in High-Risk Early TNBC

December 8th 2023

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

MammaPrint Predicts Likelihood of pCR With Neoadjuvant Chemo in HR+/HER2– Early Breast Cancer

December 8th 2023

Real-world data support the use of the MammaPrint index as a predictor of neoadjuvant chemosensitivity in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Obesity May Contribute to Biological Differences in Breast Cancer Tumors

December 8th 2023

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

December 8th 2023

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.